Dünya

Revolutionary Cancer Vaccine Developed by UMass Amherst Researchers

Groundbreaking Research Results in 88% Tumor-Free Mice A recent study conducted by the Biomedical Engineering Department at the University of Massachusetts Amherst has revealed that up to 88% of mice…

0 Yorum Yapıldı
Bağlantı kopyalandı!
Revolutionary Cancer Vaccine Developed by UMass Amherst Researchers

Groundbreaking Research Results in 88% Tumor-Free Mice

A recent study conducted by the Biomedical Engineering Department at the University of Massachusetts Amherst has revealed that up to 88% of mice vaccinated remained tumor-free. The findings indicate that the vaccine not only shrinks existing tumors but also has the potential to prevent cancer from developing.

Nanoparticles Activating Immune System in Multiple Ways

The lead author of the study, Prof. Prabhani Atukorale, explained, “We designed these nanoparticles to activate the immune system through multiple pathways. When combined with cancer-related antigens, we can significantly halt tumor growth.”

Revolutionizing Cancer Immunotherapy

Traditional vaccines introduce an antigen from the disease agent into the body along with an immune-stimulating adjuvant. However, finding a suitable adjuvant for cancer vaccines has been challenging. To overcome this obstacle, researchers developed a “lipid nanoparticle-based super adjuvant” containing two different adjuvants. This structure enabled the immune system to more effectively recognize and eliminate cancer cells.

Impressive Results from Experiments

When mice were given the super vaccine, 80% were completely protected against melanoma, while none of the mice receiving the traditional vaccine survived more than 35 days. Furthermore, metastasis to the lungs was completely prevented.

In a second phase of the study, researchers conducted a more realistic test using dead cancer cells directly extracted from the tumor. The results showed:

  • 88% tumor rejection in pancreatic cancer,
  • 75% in breast cancer,
  • 69% in melanoma.

No mice exhibited cancer spreading to other parts of the body.

Human Trials on the Horizon

The research outcomes were published in the Cell Reports Medicine journal. The vaccine, yet to be tested on humans, could potentially serve as a universal platform against multiple cancer types.

Dr. Griffin Kane, a co-author of the study, stated, “Generating tumor-specific T-cell responses is the key factor behind the survival difference.”

Experts suggest that if this technology advances to clinical trials, it could become one of the first treatment methods capable of completely halting cancer spread in the body.

Benzer Haberler

Tümü
ABD İstihbaratından Hamaney İddiası Müzakereleri Yavaşlatıyor
ABD İstihbaratından Hamaney İddiası Müzakereleri Yavaşlatıyor
Macron Norveç’in Fransa Nükleer Caydırıcılık Sistemine Dahil Olduğunu Açıkladı
Macron Norveç’in Fransa Nükleer Caydırıcılık Sistemine Dahil Olduğunu Açıkladı
Pakistan ve ABD Dışişleri Bakanları Washingtonda İlişkileri Masaya Yatırdı
Pakistan ve ABD Dışişleri Bakanları Washingtonda İlişkileri Masaya Yatırdı
İran’da İnternet Kısıtlamaları Kaldırıldı Pezeşkiyan Onay Verdi
İran’da İnternet Kısıtlamaları Kaldırıldı Pezeşkiyan Onay Verdi
Netanyahu Trump ile İran Nükleer Tehdidi Konusunda Anlaştı
Netanyahu Trump ile İran Nükleer Tehdidi Konusunda Anlaştı
Fransa İsrailli Bakan Ben Gvir’in Ülkeye Girişini Yasakladı
Fransa İsrailli Bakan Ben Gvir’in Ülkeye Girişini Yasakladı
Muhtemel.net Haberin Doğru Adresi
Muhtemel

Muhtemel.net, ziyaretçilerine Gündem, Dünya, Eğitim, Ekonomi, Magazin, Sağlık, Spor, Teknoloji ve Yaşam gibi çeşitli kategorilerde zengin içerikler sunan bir platformdur. İlginizi çeken konularda daha fazla bilgi edinmek için sitemizi keşfedin.

2025 Muhtemel.net © Tüm hakları saklıdır.